ATE326948T1 - Zusammensetzung geeignet zur behandlung der pferdelahmheit - Google Patents

Zusammensetzung geeignet zur behandlung der pferdelahmheit

Info

Publication number
ATE326948T1
ATE326948T1 AT97948262T AT97948262T ATE326948T1 AT E326948 T1 ATE326948 T1 AT E326948T1 AT 97948262 T AT97948262 T AT 97948262T AT 97948262 T AT97948262 T AT 97948262T AT E326948 T1 ATE326948 T1 AT E326948T1
Authority
AT
Austria
Prior art keywords
treatment
lameness
horse
composition suitable
donor
Prior art date
Application number
AT97948262T
Other languages
German (de)
English (en)
Inventor
Meri Charmyne Russell
Original Assignee
Cellegy Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellegy Pharma Inc filed Critical Cellegy Pharma Inc
Application granted granted Critical
Publication of ATE326948T1 publication Critical patent/ATE326948T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97948262T 1996-11-19 1997-11-17 Zusammensetzung geeignet zur behandlung der pferdelahmheit ATE326948T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/752,415 US5891472A (en) 1996-11-19 1996-11-19 Treatment of equine laminitis

Publications (1)

Publication Number Publication Date
ATE326948T1 true ATE326948T1 (de) 2006-06-15

Family

ID=25026227

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948262T ATE326948T1 (de) 1996-11-19 1997-11-17 Zusammensetzung geeignet zur behandlung der pferdelahmheit

Country Status (10)

Country Link
US (3) US5891472A (enExample)
EP (1) EP0946147B1 (enExample)
JP (1) JP2001509136A (enExample)
AT (1) ATE326948T1 (enExample)
AU (1) AU5435998A (enExample)
BR (1) BR9714573A (enExample)
CA (1) CA2273183A1 (enExample)
DE (1) DE69735949T2 (enExample)
ES (1) ES2263182T3 (enExample)
WO (1) WO1998022090A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
KR100464601B1 (ko) * 1998-10-23 2004-12-31 이데아 악티엔게젤샤프트 페이로드를 증가시키고, 분리/결합율을 제어하기 위한 거대 분자 결합체 및 복합응집체의 생장, 시험 및 사용방법
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
CN1267212C (zh) * 2000-08-11 2006-08-02 大卫·R·怀特洛克 氨氧化细菌在药物中的应用、由其制成的制剂及用其处理过的用品
JP2002136025A (ja) * 2000-10-26 2002-05-10 Mitsubishi Electric Corp 電磁機器
US6780849B2 (en) 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
JP2005515218A (ja) * 2002-01-11 2005-05-26 ホイットロック，デービッド，アール． アンモニア酸化細菌を含む組成物およびその使用方法
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20040092819A1 (en) * 2002-08-16 2004-05-13 Hmt High Medical Technologies Ag Method for treating laminitis in horses, ponies and other equines with acoustic waves
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US6936273B2 (en) * 2002-12-20 2005-08-30 Idexx Laboratories, Inc. Liposomal analgesic formulation and use
CA2539974A1 (en) * 2003-09-26 2005-04-07 David R. Whitlock Methods of using ammonia oxidizing bacteria
WO2005081964A2 (en) * 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
CA2563670C (en) * 2004-04-19 2014-09-16 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
KR20070086045A (ko) * 2004-11-12 2007-08-27 이데아 아게 피부 상태 치료에서의 확대된 표면 집합체
US7731993B2 (en) * 2004-11-17 2010-06-08 Lindsey Berkson Composition for treating a dermal anomaly
JP2008520694A (ja) * 2004-11-17 2008-06-19 リンジー・バークソン 非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法
CA2606565C (en) 2005-05-27 2016-05-10 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US7744928B2 (en) * 2006-04-14 2010-06-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treatment of lesioned sites of body vessels
US7975699B2 (en) 2007-10-30 2011-07-12 The Invention Science Fund I, Llc Condoms configured to facilitate release of nitric oxide
US8221690B2 (en) 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US7862598B2 (en) 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
WO2008126088A2 (en) * 2007-04-15 2008-10-23 Oron Zachar Anti-pyretic vasodilators
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US7846400B2 (en) * 2007-10-30 2010-12-07 The Invention Science Fund I, Llc Substrates for nitric oxide releasing devices
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US20110105480A1 (en) * 2008-06-24 2011-05-05 Keith Freehauf Pharmaceutical transdermal compositions and method for treating inflammation in cattle
US20100227895A1 (en) * 2009-03-05 2010-09-09 Mpco- The Magic Powder Company Method for treating equine laminitis
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
US8604081B2 (en) 2009-06-24 2013-12-10 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
CN102711729B (zh) 2009-08-21 2015-04-01 诺万公司 局部用凝胶
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2658551B1 (en) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
EP2658554A4 (en) 2010-12-29 2015-01-07 Strategic Science & Tech Llc SYSTEMS AND METHOD FOR THE TREATMENT OF ALLERGIES AND OTHER INDICATIONS
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
WO2014163030A1 (ja) 2013-04-01 2014-10-09 第一三共株式会社 馬の炎症治療のための製剤
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
KR102607213B1 (ko) 2014-04-15 2023-11-30 에이오바이오미 엘엘씨 암모니아-산화 니트로소모나스 유트로파 균주 d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
GB2571235B (en) * 2016-11-09 2021-05-19 Provita Eurotech Ltd Antimicrobial formulations for the treatment of veterinary hoof infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2440371A1 (fr) * 1978-10-31 1980-05-30 Fisons Ltd Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
IE54286B1 (en) * 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
CH681427A5 (enExample) * 1987-07-01 1993-03-31 Zambon Spa
CH680223A5 (enExample) * 1989-07-17 1992-07-15 Pier Luigi Prof Dr Luisi
DE4305881C1 (de) * 1993-02-26 1994-03-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
WO1995006467A1 (en) * 1993-08-28 1995-03-09 The University Of Sheffield Treatment of laminitis
GB2292520B (en) * 1994-08-25 1998-09-02 Univ Sheffield Transdermal dressings for animals
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis

Also Published As

Publication number Publication date
EP0946147B1 (en) 2006-05-24
DE69735949T2 (de) 2007-01-04
DE69735949D1 (de) 2006-06-29
JP2001509136A (ja) 2001-07-10
ES2263182T3 (es) 2006-12-01
US6045827A (en) 2000-04-04
EP0946147A4 (en) 2001-12-12
AU5435998A (en) 1998-06-10
US5891472A (en) 1999-04-06
US6287601B1 (en) 2001-09-11
WO1998022090A1 (en) 1998-05-28
CA2273183A1 (en) 1998-05-28
BR9714573A (pt) 2002-07-23
EP0946147A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
ATE326948T1 (de) Zusammensetzung geeignet zur behandlung der pferdelahmheit
BR9507730A (pt) Uso de formulações em gel como composições de tratamento
FR2751878B1 (fr) Utilisation dans une composition d'un extrait d'au moins une labiee
ATE311184T1 (de) 1-benzyl-3-(substituiertes-hetaryl)-kondensiert n pyrazol-derivaten zur behandlung von erkrankungen des herz-kreislaufsystems und des zentralnervensystems
ATE264685T1 (de) Angesäuertes nitrit zur verwendung als antimikrobielles mittel
DE69724804D1 (de) Pestizide zusammensetzung und verfahren zur anwendung
ATE218868T1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
ATE121287T1 (de) Verfahren zur behandlung der alopezie.
KR970703762A (ko) N- 아세틸- l- 시스테인을 포함하는 국소용 조성물(topical compositions comprising n-acetyl-l-cysteine)
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
ATE212841T1 (de) Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DK227090A (da) Organisk guldkompleks til topisk anvendelse
BR9908713A (pt) Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
DE60028063D1 (de) TEILCHEN FüR FLüSSIGE ZUBEREITUNGEN
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
PT920336E (pt) Pesticidas que compreendem alcaloides da benzofenantridina
BR9508668A (pt) Composições herbicidas que contêm dmso
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
ATE338768T1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
DK1054681T3 (da) Veterninærmedicinsk anvendelse af kombinationer af aktive midler bland antibiotika og terpenholdige planteekstrakter
ATE200026T1 (de) Behandlung von laminitis
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
UA9671A (uk) Препарат "кг" для лікування копитної гнилі тварин
HRP921303A2 (en) Preparation for hardening horny tissues of mammalians

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties